Trials / Completed
CompletedNCT05489718
A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema
A Dose Escalation Phase I Clinical Study to Evaluate the Tolerability and Safety of IBI324 in Subjects With Diabetic Macular Edema(DME)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed as a Multi-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single and multiple intravitreal injections of IBI324 in subjects with DME
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IBI324 | Dose 2 IBI324 of multiple IVT injection |
| BIOLOGICAL | IBI324 | Dose 2 IBI324 of single IVT injection |
| BIOLOGICAL | IBI324 | Dose 1 IBI324 of single IVT injection |
| BIOLOGICAL | IBI324 | Dose 3 IBI324 of single IVT injection |
| BIOLOGICAL | IBI324 | Dose 3 IBI324 of multiple IVT injection |
Timeline
- Start date
- 2022-08-01
- Primary completion
- 2023-06-05
- Completion
- 2023-06-05
- First posted
- 2022-08-05
- Last updated
- 2023-10-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05489718. Inclusion in this directory is not an endorsement.